Guggenheim maintains Adicet Bio at Buy, lowers price target to $55 from $90
Guggenheim kept Adicet Bio's rating at Buy but reduced its price target to $55 from $90, a 38.9% cut. This implies a 1783.6% upside from the Nov 5 close of $2.92, according to the firm.
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 4:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Decision brief
The 30-second read
Med
01
Why it matters
The analyst's target reduction reflects concerns about near‑term milestones.
02
Market read
Analyst downgrade may trigger short‑term sell pressure in ADCT.
03
What to watch
Upcoming clinical trial data could offset the target reduction.
Relevance 5/10Novelty 5/10Timing: today
Background
Adicet Bio is a clinical‑stage biotech focused on oncology therapies.
Market effects
Sector
May weigh on other small‑cap biotech stocks as analysts reassess valuations.
Regional
Limited to US biotech sector.
Global
Low global impact.
Counterpoint
What could challenge this read
Some investors may view the cut as an overreaction and see upside potential.
Key entities
- Analyst FirmGuggenheim
Provided the rating and price target update.
